NEW YORK (GenomeWeb News) — Vanderbilt University Medical Center is building a center that will study how proteomics and molecular markers can help develop diagnostics and drugs for cancer, the school said today.
Vanderbilt’s Center for Proteomics and Drug Actions is funded by a $1 million, five-year grant from the National Foundation for Cancer Research and will be linked with seven other university research centers in the US, UK, and in China, Vanderbilt said.
The school said researchers at the center will work to “develop new technology that will reveal how drugs interact with protein targets, both therapeutic and the potential side-effects.”
The university said it sought to build the center after it recognized that proteomic tools can help discover molecular markers that may lead to diagnostics, drug targets, “new endpoints for accelerating clinical trials.”
The grant will be used in large part to extend research conducted by Vanderbilt researcher Larry Marnett, who has developed techniques to make drug agents bind tightly with targets to create markers that are easy to detect and extract.